cov prevalence: Seroprevalence of COVID-19

Sponsor

Sohag University (Other)

Overall Status

Recruiting

CT.gov ID

NCT04941053

Collaborator

(none)

300

Enrollment

Location

3.9

Anticipated Duration (Months)

76.7

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Coronavirus disease pandemic has been started in late 2019. Since this date, the number of cases has been increased reaching 32.7 million cases worldwide in 27 September, 2020. . Herd immunity is achieved when enough people become immune to a virus to stop its spread. Around 70% to 90% of a population needs to be immune to protect the uninfected. In A Spanish study of more than 30,000 people estimates that around just 5% of the Spanish population has developed antibodies

Condition or Disease	Intervention/Treatment	Phase
Covid19	Diagnostic Test: laboratory test

Detailed Description

Aims of work:

A cross-sectional study to detect the seroprevalence to COVID 19 in chronic hemodialysis patients and compare it with the COVID 19 seroprevalence in healthy control in Sohag governorate Egypt

Methods:

After taken informed consent according to Sohag University Ethical Committee A questionnaire on coronavirus symptoms will be asked including epidemiological characters and history of previous COVID 19 infection and infection control measures to prevent it

5 ml of the blood sample will be taken for IgG antibodies testing with a chemiluminescent microparticle immunoassay.

Study Design

Study Type:

Observational [Patient Registry]

Anticipated Enrollment :

300 participants

Observational Model:

Case-Control

Time Perspective:

Cross-Sectional

Official Title:

Seroprevalence of COVID19 in Sohag Governorate Egypt

Actual Study Start Date :

Jun 3, 2021

Anticipated Primary Completion Date :

Aug 30, 2021

Anticipated Study Completion Date :

Sep 30, 2021

Arms and Interventions

Arm	Intervention/Treatment
group 1 chronic haemodialysis patients seroprevalnce of COVID 19	Diagnostic Test: laboratory test seroprevalnce
healthy control seroprevalnce of COVID 19	Diagnostic Test: laboratory test seroprevalnce

Arm

Intervention/Treatment

group 1 chronic haemodialysis patients

seroprevalnce of COVID 19

Diagnostic Test: laboratory test

seroprevalnce

healthy control

seroprevalnce of COVID 19

Diagnostic Test: laboratory test

seroprevalnce

Outcome Measures

Primary Outcome Measures

seroprevalnce [3-6-2021 to 30-8-2021]
antibody measurement

Eligibility Criteria

Criteria

Ages Eligible for Study:

N/A and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

patient accept to participate

Exclusion Criteria:

vaccinated people

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Sohag University	Sohag		Egypt	82733

Sponsors and Collaborators

Sohag University

Investigators

Principal Investigator: N S shafik, lecturer, sohag university hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

Noha Saber Shafik, lecturer, Sohag University

ClinicalTrials.gov Identifier:

NCT04941053

Other Study ID Numbers:

Soh-Med-21-04-33

First Posted:

Jun 28, 2021

Last Update Posted:

Jun 30, 2021

Last Verified:

Jun 1, 2021

Individual Participant Data (IPD) Sharing Statement:

Plan to Share IPD:

Studies a U.S. FDA-regulated Drug Product:

Studies a U.S. FDA-regulated Device Product:

Additional relevant MeSH terms:

COVID-19

Study Results

No Results Posted as of Jun 30, 2021